Stock fact sheet · data as of
Zevra Therapeutics, Inc. (ZVRA): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · High Growth
Is ZVRA undervalued?
At 10.23 (close of 16 Oct 2026), ZVRA trades 62% below the GLS average fair value of 27.02. That average comes from 7 models run on the latest filings, and 6 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Zevra Therapeutics, Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
There is a wide gap between Graham Number (9.03) and GLS Growth (60.30). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files ZVRA under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for ZVRA
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 9.03 | -12% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 50.55 | +394% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 21.67 | +112% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 60.30 | +489% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 14.84 | +45% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 21.84 | +113% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 10.94 | +7% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 1.56 | -85% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 25.75 | +152% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Zevra Therapeutics, Inc. scores 6 of 9 on the Piotroski F-score: a middling result that passes the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 3.2/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are high - ROIC 38.2%, ROE 53.8%, ROA 29.2% - with debt at 0.41 times equity and a free-cash-flow yield of 5.4%.
Zevra Therapeutics, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from License 100% (quarter Q2 FY2024).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 6 / 9 | ROIC | 38.2% |
|---|---|---|---|
| GLS Moat | 3.2 / 10 | ROE | 53.8% |
| Debt / equity | 0.41 | ROA | 29.2% |
| Free-cash-flow yield | 5.4% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 70: Good
With a Wheel Score of 70 - the Good band - Zevra Therapeutics, Inc. clears the Sunday Scan's "70 or higher" rule. The parts: Value 25/25, Health 13/20, Moat 5/15, Premium 14/20, Stability 13/20; Moat (5/15) scores lowest.
Implied volatility is 85% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (14 of 20) because volatility this high usually comes with a reason. The option chain is deep: 76,316 contracts of open interest across all expiries, which means tight fills at most strikes.
Volume runs at 753k shares a day on a market cap of $607M, with a beta of 0.98; the Stability part of the Wheel Score gives that 13 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 62% margin of safety | |
| Health | 13 / 20 | Piotroski 6/9 | |
| Moat | 5 / 15 | moat 3.2/10 | |
| Premium | 14 / 20 | implied volatility 85% | |
| Stability | 13 / 20 | 753k shares/day, $607M cap, beta 0.98 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 4 Nov 2026 (after the close), 19 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Zevra Therapeutics, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| WVE Wave Life Sciences Ltd. | 3.09 | 1.35 | -128% | 30Weak | $609M |
| OLMA Olema Pharmaceuticals, Inc. | 6.87 | 0.4892 | -1304% | 24Weak | $601M |
| PHAT Phathom Pharmaceuticals, Inc. | 7.40 | - | - | 41Weak | $599M |
| NVCT Nuvectis Pharma, Inc. | 18.93 | 1.18 | -1506% | 24Weak | $618M |
| ANNX Annexon, Inc. | 3.60 | 0.7891 | -356% | 24Weak | $590M |
| CLYM Climb Bio, Inc. | 10.91 | 0.4867 | -2142% | 23Weak | $627M |
| SLDB Solid Biosciences Inc. | 5.47 | 0.4110 | -1230% | 22Weak | $586M |
| CRMD CorMedix Inc. | 7.46 | 83.15 | +91% | 69Good | $581M |
| ANL Adlai Nortye Ltd. | 12.09 | 0.4209 | -2773% | 23No options | $642M |
| AVTX Avalo Therapeutics, Inc. | 12.01 | 0.9861 | -1118% | 26Weak | $644M |
| PRME Prime Medicine, Inc. | 3.13 | - | - | 35Weak | $568M |
| DSGN Design Therapeutics, Inc. | 10.48 | 0.2574 | -3971% | 25Weak | $656M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ZVRA
Is ZVRA undervalued right now?
By the GLS models, yes: at 10.23 the stock is 62% below the average fair value of 27.02 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of ZVRA and what does it mean?
ZVRA scores 70 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for ZVRA?
27.02 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Zevra Therapeutics, Inc. report earnings next?
The next earnings report is due on 4 Nov 2026 (after the close), 19 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does ZVRA have listed options, and how liquid are they?
Yes. The nightly snapshot found 336 listed contracts with 76,316 open interest across all expiries and implied volatility of 85% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.